TLIS insider filings
Talis Biomedical Corp — 43 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-09-09. Screen TLIS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for TLIS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Talis Biomedical Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-09-09 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 5,100 @ $1.40 · Purchase (P): 25,000 @ $1.48 | EDGAR |
| 2024-09-05 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 500 @ $4 | EDGAR |
| 2024-09-04 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 151 @ $4.25 | EDGAR |
| 2024-08-28 | 4 | Leonard Braden Michael — 10% owner | Purchase (P): 13,167 @ $3.90 · Purchase (P): 1,215 @ $3.96 | EDGAR |
| 2023-08-02 | 4 | Lukowiak Andrew A — President | Grant/award (A): 30,575 (derivative) @ $0 | EDGAR |
| 2023-07-18 | 4 | Markovich Rebecca — Interim CFO | Grant/award (A): 13,071 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner BAKER JULIAN — Director, 10% owner BAKER FELIX — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner | Grant/award (A): 23,685 (derivative) @ $0 · Grant/award (A): 23,685 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Gilliam Melissa — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Ismagilov Rustem F. — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Posard Matthew L. — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Dreismann Heinrich — Director | Grant/award (A): 5,466 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Scott Randal W. — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Popovits Kimberly J — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2023-05-23 | 4 | Dreismann Heinrich — Director | Grant/award (A): 190,000 (derivative) @ $0 | EDGAR |
| 2023-04-11 | 4 | Kelley Robert J. — Chief Executive Officer, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2023-04-11 | 4 | Moody John Roger Jr — Chief Financial Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Ismagilov Rustem F. — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Gilliam Melissa — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Posard Matthew L. — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Scott Randal W. — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Popovits Kimberly J — Director | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner BAKER JULIAN — Director, 10% owner BAKER FELIX — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner | Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2022-06-02 | 4 | Kelley Robert J. — Chief Executive Officer, Director | Grant/award (A): 723,560 (derivative) @ $0 | EDGAR |
| 2022-06-02 | 4 | Moody John Roger Jr — Chief Financial Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2021-12-09 | 4 | Kelley Robert J. — Chief Executive Officer, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2021-12-02 | 4 | Blaser Brian J — President and CEO, Director | Grant/award (A): 750,000 (derivative) @ $0 · Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner BAKER JULIAN — Director, 10% owner BAKER FELIX — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner | Purchase (P): 50,000 @ $4.37 | EDGAR |
| 2021-10-05 | 4 | Liu Douglas — Chief Operating Officer | Grant/award (A): 200,000 (derivative) | EDGAR |
| 2021-10-05 | 4 | Kelley Robert J. — Chief Commercial Officer | Grant/award (A): 130,000 (derivative) | EDGAR |
| 2021-10-05 | 4 | Moody John Roger Jr — Chief Financial Officer | Grant/award (A): 130,000 (derivative) | EDGAR |
| 2021-08-31 | 4 | Popovits Kimberly J — Interim CEO | Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2021-08-17 | 4 | Ramakrishnan Ramesh | Option exercise (M): 43,614 @ $1.50 · Option exercise (M): 8,741 @ $1.50 · Sale (S): 27,502 @ $7.66 · Option exercise (M): 43,614 (derivative) @ $0 · Option exercise (M): 8,741 (derivative) @ $0 | EDGAR |
| 2021-05-18 | 4 | Scott Randal W. — Director | Purchase (P): 9,000 @ $10.16 · Purchase (P): 11,000 @ $10.11 | EDGAR |
| 2021-03-18 | 4 | HILLEMAN JERYL L — Director | Grant/award (A): 35,112 (derivative) @ $0 | EDGAR |
| 2021-02-19 | 4 | Ramakrishnan Ramesh — Sr. Vice President, R&D | Purchase (P): 1,000 @ $16 | EDGAR |
| 2021-02-19 | 4 | Liu Douglas — Sr. Vice President, Operations | Purchase (P): 4,000 @ $16 | EDGAR |
| 2021-02-19 | 4 | Flick Karen E. — Chief of Staff, Sr. VP, Legal | Purchase (P): 2,000 @ $16 | EDGAR |
| 2021-02-19 | 4 | Coe Brian — Chief Executive Officer, Director | Conversion (C): 15,082 · Conversion (C): 8,416 · Conversion (C): 7,433 · Conversion (C): 21,568 (derivative) @ $0 · Conversion (C): 12,035 (derivative) @ $0 · Conversion (C): 10,630 (derivative) @ $0 | EDGAR |
| 2021-02-19 | 4 | Posard Matthew L. — Director | Purchase (P): 62,500 @ $16 | EDGAR |
| 2021-02-19 | 4 | Moody John Roger Jr — Chief Financial Officer | Purchase (P): 1,700 @ $16 | EDGAR |
| 2021-02-19 | 4 | Scott Randal W. — Director | Conversion (C): 752,897 · Conversion (C): 334,546 · Conversion (C): 302,621 · Purchase (P): 312,500 @ $16 · Conversion (C): 1,076,643 (derivative) @ $0 · Conversion (C): 478,402 (derivative) @ $0 · +1 more | EDGAR |
| 2021-02-19 | 4 | Popovits Kimberly J — Director | Conversion (C): 22,041 · Conversion (C): 209,790 · Purchase (P): 5,300 @ $16 · Conversion (C): 92,057 · Conversion (C): 89,968 · Conversion (C): 31,519 (derivative) @ $0 · +3 more | EDGAR |
| 2021-02-19 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner 667, L.P. — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Purchase (P): 457,462 @ $16 · Purchase (P): 5,792,538 @ $16 · Grant/award (A): 767,106 (derivative) @ $8.55 · Grant/award (A): 9,191,433 (derivative) @ $8.55 · Option exercise (M): 4,975 (derivative) · Option exercise (M): 963,490 (derivative) · +18 more | EDGAR |
Recent 8-K events — Talis Biomedical Corp
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-09-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-05 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-23 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-04-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TLIS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs